Last edition
News about "Pfizer oncology portfolio"
Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.
Pfizer Oncology Portfolio | 01/06/2026 | By News Bureau
Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development
Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.
Pfizer Oncology Portfolio | 29/05/2026 | By News Bureau | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy